RT Journal Article
SR Electronic
T1 A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.20.20157651
DO 10.1101/2020.07.20.20157651
A1 Mitjà, Oriol
A1 Ubals, Maria
A1 Corbacho-Monné, Marc
A1 Alemany, Andrea
A1 Suñer, Clara
A1 Tebe, Cristian
A1 Tobias, Aurelio
A1 Peñafiel, Judith
A1 Ballana, Ester
A1 Pérez, Carla A.
A1 Admella, Pol
A1 Riera-Martí, Nuria
A1 Laporte, Pep
A1 Mitja, Jordi
A1 Clua, Mireia
A1 Bertran, Laia
A1 Sarquella, Maria
A1 Gavilán, Sergi
A1 Ara, Jordi
A1 Argimon, Josep M
A1 Cuatrecasas, Gabriel
A1 Cañadas, Paz
A1 Elizalde-Torrent, Aleix
A1 Fabregat, Robert
A1 Farré, Magí
A1 Forcada, Anna
A1 Flores-Mateo, Gemma
A1 López, Cristina
A1 Muntada, Esteve
A1 Nadal, Núria
A1 Narejos, Silvia
A1 Gil-Ortega, Aroa N
A1 Prat, Nuria
A1 Puig, Jordi
A1 Quiñones, Carles
A1 Ramírez-Viaplana, Ferran
A1 Urueña, Juliana Reyes-
A1 Riveira-Muñoz, Eva
A1 Ruiz, Lidia
A1 Sanz, Sergi
A1 Sentis, Alexis
A1 Sierra, Alba
A1 Velasco, César
A1 Vivanco-Hidalgo, Rosa Maria
A1 Zamora, Juani
A1 ,
A1 Casabona, Jordi
A1 Vall-Mayans, Martí
A1 G-Beiras, Camila
A1 Clotet, Bonaventura
YR 2020
UL http://medrxiv.org/content/early/2020/07/26/2020.07.20.20157651.abstract
AB Background Current strategies for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are limited to non-pharmacological interventions. Hydroxychloroquine (HCQ) has been proposed as a postexposure therapy to prevent Coronavirus disease 2019 (Covid-19) but definitive evidence is lacking.Methods We conducted an open-label, cluster-randomized trial including asymptomatic contacts exposed to a PCR-positive Covid-19 case in Catalonia, Spain. Clusters were randomized to receive no specific therapy (control arm) or HCQ 800mg once, followed by 400mg daily for 6 days (intervention arm). The primary outcome was PCR-confirmed symptomatic Covid-19 within 14 days. The secondary outcome was SARS-CoV-2 infection, either symptomatically compatible or a PCR-positive result regardless of symptoms. Adverse events (AEs) were assessed up to 28 days.Results The analysis included 2,314 healthy contacts of 672 Covid-19 index cases identified between Mar 17 and Apr 28, 2020. A total of 1,198 were randomly allocated to usual care and 1,116 to HCQ therapy. There was no significant difference in the primary outcome of PCR-confirmed, symptomatic Covid-19 disease (6.2% usual care vs. 5.7% HCQ; risk ratio 0.89 [95% confidence interval 0.54-1.46]), nor evidence of beneficial effects on prevention of SARS-CoV-2 transmission (17.8% usual care vs. 18.7% HCQ). The incidence of AEs was higher in the intervention arm than in the control arm (5.9% usual care vs 51.6% HCQ), but no treatment-related serious AEs were reported.Conclusions Postexposure therapy with HCQ did not prevent SARS-CoV-2 disease and infection in healthy individuals exposed to a PCR-positive case. Our findings do not support HCQ as postexposure prophylaxis for Covid-19.ClinicalTrials.gov registration number NCT04304053Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04304053Funding StatementCrowdfunding campaign YoMeCorono (https://www.yomecorono.com/), Laboratorios Rubio, Laboratorios Gebro Pharma, Zurich Seguros, SYNLAB Barcelona, and Generalitat de Catalunya. Laboratorios Rubio also contributed to the study with the required doses of hydroxychloroquine (Dolquine).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol and subsequent amendments were approved by the institutional review board of Hospital Germans Trias Pujol, and the Spanish Agency of Medicines and Medical Devices.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study protocol and raw data will be available for a year upon request to the corresponding author